SecBot SecBot

ARQT

Arcutis Biotherapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001787306 Biotech & Drug Discovery
$28.26 +0.73 (+2.65%)
Nov 13 4:00 PM ET · prev $27.53
Market cap
$3.5B
Mid cap
Consensus
Buy
86% Buy or better · 14 analysts
Median target
$40.00
+42% · range $34.00–48.00
1 year
+8.0%
from $26.17 · Nov 17
30 days
−11.4%
from $31.89
52-week range
$19.50–34.05
−17% from high · low May 19
Avg volume 20D
2.60M
Nov 5 spike 7.60M
Short interest
18.16M
≈14.4% of shares · −11.4%
Days to cover
7.6
at average volume
Insider net
−$4.2M
0 buyers · 6 sellers · since Jun 5
New fund stakes
1
Q3 2026 13F · 1 exit
Filing reports
31
analyzed by SecBot
SecBot read MIXED 20 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed · 18 neutral oldest → newest, height = score
Avg score ·High conf. 16/20 ·Next FDA decision date, Feb 23, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $4.2M.

  • InstitutionsBULLISH

    Q3 2026: 39 added (1 new), 8 trimmed or exited. Largest new: Public Sector Pension Investment Board $20.3M.

  • AnalystsBULLISH

    12 of 14 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.228 → $0.197 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −11.4% to 18.16M shares. 7.6 days to cover, ≈14.4% of shares.

  • TrendUPTREND

    3% above its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
1
exit
$20.3M
in new stakes
FundMoveSharesValue
BlackRock, Inc.ADD19,171,035$506.7M
STATE STREET CORPADD7,718,628$204.0M
UBS Group AGADD5,533,053$146.2M
VANGUARD PORTFOLIO MANAGEMENT LLCADD3,817,697$100.9M
PRINCIPAL FINANCIAL GROUP INCDOUBLED803,525$21.2M
Squarepoint Ops LLCADD776,826$20.5M
PUBLIC SECTOR PENSION INVESTMENT BOARDNEW774,309$20.3M
JUPITER ASSET MANAGEMENT LTDDOUBLED709,620$18.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 86% rate it Buy or better
Strong Buy4Buy8Hold2Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +42%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 5, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Oct 19, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Oct 15, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Aug 6, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Aug 6, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 6, 2026Needham
MAINTAIN
MAINTAINBuy

Washington

Corporate Lobbying

2 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$4.2M
sold · 6 insiders
DateInsiderTypeValue
Nov 4, 2026
Matsuda Masaru
EVP, Chief Legal Officer
Nov 4, 2026
EXERCISE$145.6K
Nov 4, 2026
Matsuda Masaru
EVP, Chief Legal Officer
Nov 4, 2026
SELL$1.4M
Nov 2, 2026
Watanabe Todd
See Remarks
Nov 2, 2026
SELL$139.5K
Nov 2, 2026
Burnett Patrick
EVP, Chief Medical Officer
Nov 2, 2026
SELL$30.0K
Nov 2, 2026
Matsuda Masaru
EVP, Chief Legal Officer
Nov 2, 2026
SELL$38.8K
Oct 23, 2026
SCOTT ROBERT A
Director
Oct 23, 2026
AWARD2,819 sh
Oct 23, 2026
SCOTT ROBERT A
Director
Oct 23, 2026
AWARD20,507 sh
Oct 23, 2026
SCOTT ROBERT A
Director
Oct 23, 2026
AWARD8,663 sh

Earnings setup

Estimates
$0.20
EPS estimate, this quarter
−14%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.20$0.14–$0.31-15.0%$163.1M
Next Q$0.06-$0.09–$0.14-52.2%$145.5M
Current FY🔒 Fresh data, subscribers only
Next FY$1.09$0.52–$1.84-19.5%$703.0M
Congressional trades
ARQT trades disclosed by members of Congress, with disclosure delay.
1 members · 2 buys / 0 sells
DateMemberType AmountDisclosed
May 29, 2026 Gilbert CisnerosDHouse ARCUTIS BIOTHERAPEUTICS INC BUY $1K–$15K Jun 8, 2026 +10d
Mar 3, 2026 Gilbert CisnerosDHouse ARCUTIS BIOTHERAPEUTICS INC BUY $1K–$15K Apr 7, 2026 +35d

Short side

FINRA· Oct 30, 2026
18,157,145
shares short
-11.4%
vs prior settlement
7.6
days to cover
≈14.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 Press
Arcutis presented caregiver-reported outcomes from the INTEGUMENT-INFANT trial of ZORYVE cream 0.05% in infants aged…
Impact 4/10
Nov 13, 2026 FDA
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% f
Nov 10, 2026 SEC
State Street Corporation filed a Schedule 13G disclosing a 6.1% passive stake in Arcutis Biotherapeutics as of…
SC 13G · Impact 3/10
Nov 6, 2026 SEC
Five institutional buyers accumulated $25.0M in ARQT during Q3 2026, led by Principal Financial Group doubling its…
INST-CLUSTER · Impact 3/10
Nov 4, 2026 SEC
Robert A. Scott filed an amended Form 3 (3/A) disclosing 17,523 shares of Arcutis Biotherapeutics common stock held…
3/A, CLUSTER, 3 · Impact 2/10
Nov 4, 2026 Insider
Matsuda Masaru acquired via exercise 40,000 shares
EVP, Chief Legal Officer @ $3.64 ($145.6K)
Nov 4, 2026 Insider
Matsuda Masaru sold 40,000 shares
EVP, Chief Legal Officer @ $34.32 ($1.4M)
Nov 2, 2026 Insider
Watanabe Todd sold 4,377 shares
See Remarks @ $31.86 ($139.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Upcoming
Recent
Nov 13, 2026
FDA
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants
Nov 6, 2026
Press release
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical…
Nov 4, 2026
Earnings
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Arcutis today reported financial results for the quarter ended September 30, 2026 and provided a business update.
Nov 4, 2026
Earnings result
ARQT Q3 2026 Earnings: EPS $0.06 (-64.5% vs est)
Oct 28, 2026
Press release
Arcutis Appoints Rob Scott, MD to Board of Directors
Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and…

SecBot reports

31 filings · 3 press releases · 1 bullish · 2 bearish · 2 mixed · 26 neutral
All ARQT filing & press-release reports (34)